Skip to main content
. 2018 Apr 26;8:6574. doi: 10.1038/s41598-018-23733-4

Table 3.

Case-case analyses of established breast cancer risk factors with E-cadherin tumor tissue expression (low/high) among ER-negative tumors.

Risk Factor Estrogen Receptor Negative Tumors
No. of Cases Cases, N
(E-cadherin Low/High)
OR (95% CI)a P-hetb
Family history of breast cancer 9
    Absent 173/660 1.0 (Ref)
    Present 60/207 1.32 (0.88–1.97) 0.18
Age at menarche 8
    ≤12 years 69/225 1.27 (0.87–1.85)
    13 years 43/182 0.94 (0.62–1.44)
    ≥14 years 81/291 1.0 (Ref) 0.34
Parity 9
    Nulliparous 27/108 0.82 (0.51–1.33)
    1 48/190 0.82 (0.56–1.21)
    ≥2 126/441 1.0 (Ref) 0.52
Age at first birth (among parous women) 6
    <20 years 18/59 1.0 (Ref)
    20–24 years 64/257 0.84 (0.46–1.54)
    25–29 years 53/144 1.26 (0.67–2.35)
    ≥30 years 22/86 0.93 (0.45–1.93) 0.32
Oral contraceptive use (among women at age ≤50 yearsc) 5
    Never 23/125 1.0 (Ref)
    Ever 37/132 1.97 (0.96–4.06) 0.06
Menopausal hormone (MH) use (among women at age >50 yearsc) 6
    Never 63/207 1.0 (Ref)
    Ever 48/154 1.25 (0.78–2.00) 0.35
Type of ever MH use (among women at age >50 yearsc) 6
    Never 63/207 1.0 (Ref)
    Estrogen only 4/27 0.46 (0.14–1.45)
    Estrogen + Progestin 14/32 1.67 (0.80–3.49)
    Unknown 30/95 1.38 (0.78–2.46) 0.16

aLogistic regression analyses were used to estimate the associations between E-cadherin tumor tissue expression and established breast cancer risk factors using E-cadherin expression levels (low vs. high) as the outcome variable and the risk factors as the independent variable, adjusted for age (10-year categories) and study site.

bP-values for heterogeneity by E-cadherin subtype were estimated using global F test, adjusted for age and study site.

cAge ≤ 50 years was used as a proxy for premenopausal status and age > 50 years was used as a proxy for postmenopausal status.

Abbreviations: OR = odds ratio, CI = confidence interval, ER = estrogen receptor

Note: For each variable, the category that has been shown to be associated with the lowest overall breast cancer risk in the literature was selected as the reference category. The case-case OR may be interpreted as the ratio of case-control ORs for E-cadherin low tumors (vs. controls) and E-cadherin high tumors (vs. controls). The case-case OR > 1 may suggest that the risk factor association is more strongly associated with E-cadherin low tumors than with E-cadherin high tumors (ORE-cadherin low vs. control > ORE-cadherin high vs. control).